Suppr超能文献

美国最后一例报告的本土野生病毒相关疾病病例出现十年后的脊髓灰质炎流行病学情况。

Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease.

作者信息

Strebel P M, Sutter R W, Cochi S L, Biellik R J, Brink E W, Kew O M, Pallansch M A, Orenstein W A, Hinman A R

机构信息

Division of Immunization, National Center for Prevention Services, Centers for Disease Control, Atlanta, Georgia 30333.

出版信息

Clin Infect Dis. 1992 Feb;14(2):568-79. doi: 10.1093/clinids/14.2.568.

Abstract

Poliomyelitis caused by wild poliovirus has been virtually nonexistent in the United States since 1980, and vaccine-associated paralytic poliomyelitis (VAPP) has emerged as the predominant form of the disease. We reviewed national surveillance data on poliomyelitis for 1960-1989 to assess the changing risks of wild-virus, vaccine-associated, and imported paralytic disease; we also sought to characterize the epidemiology of poliomyelitis for the period 1980-1989. The risk of VAPP has remained exceedingly low but stable since the mid-1960s, with approximately 1 case occurring per 2.5 million doses of oral poliovirus vaccine (OPV) distributed during 1980-1989. Since 1980 no indigenous cases of wild-virus disease, 80 cases of VAPP, and five cases of imported disease have been reported in the United States. Three distinct groups are at risk of vaccine-associated disease: recipients of OPV (usually infants receiving their first dose), persons in contact with OPV recipients (mostly unvaccinated or inadequately vaccinated adults), and immunologically abnormal individuals. Overall, 93% of cases in OPV recipients and 76% of vaccine-associated cases have been related to administration of the first or second dose of OPV. Our findings suggest that adoption of a sequential vaccination schedule (inactivated poliovirus vaccine followed by OPV) would be effective in decreasing the risk of VAPP while retaining the proven public health benefits of OPV.

摘要

自1980年以来,野生脊髓灰质炎病毒引起的脊髓灰质炎在美国几乎已不存在,疫苗相关麻痹型脊髓灰质炎(VAPP)已成为该疾病的主要形式。我们回顾了1960 - 1989年脊髓灰质炎的全国监测数据,以评估野生病毒、疫苗相关及输入性麻痹疾病风险的变化;我们还试图描述1980 - 1989年期间脊髓灰质炎的流行病学特征。自20世纪60年代中期以来,VAPP的风险一直极低且稳定,在1980 - 1989年期间,每分发约250万剂口服脊髓灰质炎病毒疫苗(OPV)会出现1例VAPP。自1980年以来,美国未报告本土野生病毒疾病病例,报告了80例VAPP和5例输入性疾病病例。有三个不同群体有患疫苗相关疾病的风险:OPV接种者(通常是首次接种的婴儿)、与OPV接种者接触的人(大多是未接种或未充分接种疫苗的成年人)以及免疫功能异常的个体。总体而言,OPV接种者中93%的病例以及76%的疫苗相关病例与第一剂或第二剂OPV的接种有关。我们的研究结果表明采用序贯接种程序(灭活脊髓灰质炎病毒疫苗后接种OPV)将有效降低VAPP的风险,同时保留OPV已证实的公共卫生益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验